Background: Few studies evaluated the effectiveness of COVID-19 antivirals specifically in the asthma population This study assessed short- and long-term effects of nirmatrelvir/ritonavir versus molnupiravir in asthma population.
Methods: This is a retrospective cohort study on adult asthma patients infected with COVID-19, using real-world data obtained from the health officials in Hong Kong. Key inclusion criteria were infection with COVID-19 between March 16, 2022, and Oct 30, 2023, age ≥ 18 years, previous asthma diagnosis, and prescription history of an asthma medication. Outcomes included acute and post-acute mortality, post-acute all-cause hospitalization, and cause-specific hospitalization.
Results: 1,745 patients were eligible for this study, with a median follow-up time of 365 days (IQR: 335-365). Patients in the nirmatrelvir/ritonavir group had significantly lower risks of acute inpatient death (HR, 0·27 [95% CI, 0·12 to 0·59]; p = 0·0011), post-acute inpatient death (HR, 0·49 [95% CI, 0·28 to 0·85]; p = 0·011), all-cause hospitalization (HR, 0·72 [95% CI, 0·58 to 0·89]; p = 0·0020), and myocardial infarction (HR, 0·10 [95% CI, 0·01 to 0·92]; p = 0·042) than patients in the control group. The risk of all-cause hospitalization was significantly lower in the nirmatrelvir/ritonavir group compared to the molnupiravir group (HR, 0·65 [95% CI, 0·52 to 0·81]; p = 0·00012). Among patients who were prescribed medium-/ high-dose inhaled corticosteroids, the nirmatrelvir/ritonavir group had a lower hazard of asthma exacerbation than the molnupiravir group (HR, 0·58 [95% CI, 0·35 to 0·95]; p = 0.030).
Conclusion: Compared with molnupiravir, nirmatrelvir/ritonavir may offer more benefits in reducing the risk of post-acute sequelae of COVID-19 among asthma patients. In addition, the post-acute benefits of the antivirals were also demonstrated in patients with mild asthma, which have not been generally recommended in existing clinical management guidelines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871785 | PMC |
| http://dx.doi.org/10.1186/s12931-025-03156-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thymic stromal lymphopoietin contributes to endometriotic lesion proliferation and disease-associated inflammation.
J Immunol
February 2025
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Endometriosis is a chronic disorder in which endometrial-like tissue presents outside the uterus. Patients with endometriosis have been shown to exhibit aberrant immune responses within the lesion microenvironment and in circulation which contribute to the development of endometriosis. Thymic stromal lymphopoietin (TSLP) is an alarmin involved in cell proliferation and the induction of T helper 2 (Th2) inflammation in various diseases, such as asthma, atopic dermatitis, and pancreatic and breast cancer.
View Article and Find Full Text PDFThe Microbiome in Asthma Heterogeneity: The Role of Multi-Omic Investigations.
Immunol Rev
March 2025
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Asthma is one of the most prevalent and extensively studied chronic respiratory conditions, yet the heterogeneity of asthma remains biologically puzzling. Established factors like exogenous exposures and treatment adherence contribute to variability in asthma risk and clinical outcomes. It is also clear that the endogenous factors of genetics and immune system response patterns play key roles in asthma.
View Article and Find Full Text PDFCohort multiple randomized controlled trial in pediatric asthma to assess the long- and short-term effects of eHealth interventions: protocol of the CIRCUS study.
Ther Adv Respir Dis
March 2025
Pediatric Department, Medisch Spectrum Twente, Enschede, The Netherlands.
Background: Asthma is one of childhood's most prevalent chronic conditions significantly impacting the quality of life. Current asthma management lacks real-time, objective, and longitudinal monitoring reflected by a high prevalence of uncontrolled asthma. Long-term home monitoring promises to establish new clinical endpoints for timely anticipation.
View Article and Find Full Text PDFSystemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves.
ERJ Open Res
March 2025
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands.
Rationale: Bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) is an effective treatment for severe COPD patients by improving lung function and quality of life. However, little is known about its effects on systemic inflammation. Therefore, the aim of our study was to investigate whether EBV treatment impacts the inflammatory cytokine profile.
View Article and Find Full Text PDFDifferent Modalities in the Management of Post-COVID-19 Olfactory Dysfunction.
Indian J Otolaryngol Head Neck Surg
January 2025
Otorhinolaryngology Department, Faculty of Medicine, Benha University, Benha, Qalyubia Egypt.
SARS-CoV-2 infection may lead to olfactory dysfunctions affecting patients' quality of life. Despite various ongoing studies, solid evidence supporting therapies, especially for COVID-19-related olfactory dysfunction, remains scarce. To assess nasal steroid, nasal vitamin A, and intranasal theophylline as treatment options for post-COVID-19 olfactory dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!